Samsung Bioepis Completes Songdo Global Center Construction... Suwon Staff to Move In by January

Samsung Bioepis Headquarters Building Exterior
[Photo provided by Incheon Free Economic Zone Authority]

[Asia Economy Reporter Park Hyesook] Samsung Bioepis, a global biopharmaceutical company, has completed the construction of a large-scale research and office facility called the Global Center in Songdo International City, Incheon Free Economic Zone.

The Incheon Free Economic Zone Authority recently announced on the 21st that Samsung Bioepis has started moving research equipment and personnel into the newly built Global Center located in the advanced industrial cluster of Songdo District 5. The move-in is expected to be completed by the end of January next year.

Samsung Bioepis was established in February 2012 as a joint venture between Samsung Biologics and the U.S. biopharmaceutical company Biogen, and has so far launched three autoimmune disease drugs and two anticancer drugs in the global market.

Additionally, an ophthalmic disease treatment drug that has completed development is currently undergoing sales approval reviews in the U.S. and Europe, and three pipelines including treatments for skeletal diseases have entered Phase 3 clinical trials.

Since its establishment in 2012, Samsung Bioepis had been located within the Samsung Biologics site in Songdo, but due to insufficient office space, about 450 of its approximately 900 employees had been working in Suwon. With the completion of the Global Center, all dispersed research and office personnel have now gathered in Songdo.

Lee Won-jae, head of the Incheon Free Economic Zone Authority, stated, "We will do our best to support Samsung Bioepis to grow further as a leading research and development company representing Songdo."

Meanwhile, Songdo currently hosts leading companies in biopharmaceutical research, development, and manufacturing such as Celltrion, Samsung Biologics, and DM Bio, while global companies like Cytiva, Merck, and Thermo Fisher are expanding their technical support projects in biopharmaceutical research and process fields.

Furthermore, with the entry of research and development companies and institutions such as the Lee Gil-ye Cancer and Diabetes Research Institute, Utah Inha DDS Research Institute, Ludacure, Medimedi, and Voronoi, a bio-industry ecosystem is being established.

This content was produced with the assistance of AI translation services.